Sponsor List




CL Precision Biomed is the parent company of the medical health industry under CheerLand Investment Group, which focuses on precision medicine industry. It Aims to providing The Best Genetic Testing and Analysis, the World's leading Precision Individualized Treatment plan and High-end Service for Health Management.




PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the environment health, food safety, life sciences, laboratory services and big data markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.





Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com




Life Healthcare Group Limited is a domestic gene detection company listed in HongKong (stock code: HKEX 00928), which is committed to promotion and application of tumor gene detection in clinical medicine and health services. Its expert team consists of top scientists from The Genomic Institute of The Norvartis Research Foundation, University of California, Tsinghua University and Peking University. It has set up medical laboratories or business segments in Beijing, Hangzhou, Guangzhou, Tianjing, Shanghai and Hongkong. and its business network has extented to 22 provinces and municipalities all over the country.It has independently developed genetic testing products for respiratory tract tumors, digestive tract tumors, breast and gynecological tumors, urinary tumors, head and neck tumors and even pan-tumors, etc., which involves early screening, auxiliary diagnosis, medication guidance, prosnotic evaluation and dynamic monitoring and other steps of course management in diagnosis and treatment of tumors. 




BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical researchand genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional proceduresand support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit www.bd.com.





Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets.With more than 50 years of insight and innovation,Agilentinstruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.





Driving innovation -- As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go.

Finding answers -- While the rate of progress is accelerating exponentially, we are only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of our imagination.

Making a difference now -- Today we are a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.
Empowering a healthy future -- We now have the ability to sequence at an unprecedented scale. Collectively, this will give us a much deeper understanding of genetics than ever before. We will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. We have only just begun.
Innovative technologies -- At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.



BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation, and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated over 1,847 publications, many in top-tier journals such as Nature and Science.

The company also contributes to scientific communication by publishing the international research journal GigaScience.

BGI’s distinguished achievements have made a significant contribution to the development of genomics throughout the world.  BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI's own BGISEQ sequencing platform, economies of scale, and expert bioinformatics resources.

BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare. BGI’s services and solutions are available in more than 50 countries around the world.



AnnoGene, as a registered trademark under Annoroad, carries out extensive R&D collaborations with local and international higher education institutions and research institutes in multi-omics level such as of genomics, transcriptomics, and epigenetics, involved areas encompassing basic research in major human diseases, plant and animal molecular breeding, genetics and evolution, microorganism and ecological environment, and with featured strength in gene expression analysis, single cell techniques, chromosome Hi-C technology, and etc., thereby providing excellent technical solutions for life science research.



Nikyang Enterprise Limited is the sole partnerin Asia for a selected group of world-renowned European manufacturers of advanced laboratory equipment. As the region’s leading supplier of innovative laboratory automation solutions,Nikyang is helping to transform QC and R&D labs in China and beyond from inefficient manual processing to fully-automated high-throughput operation. Nikyangalso adds value for customersacross a wide range of sectors from pharmaceuticals,clinical & diagnosis,food to government labs,petrochemicalsand university research centres.Its flexible integrated and upgradablemodular robotic platforms are backed up by comprehensive consultancy, service and support through the company’s extensive sales network.






WuXi NextCODE is a fully integrated contract genomics organization building the global standard platform for genomic data. With offices in Shanghai; Kendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we serve the leading population genomics, precision medicine, diagnostics and wellness initiatives and enterprises using the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a Wuxi Group company. Visit us on the web at www.wuxinextcode.com.



CIMC Cold Cloud Supply Chain Management (Beijing) co., LTD is a subsidiary of CIMC Group. It is a integrated service-oriented enterprise which can provide research, development, sales and leasing of cold chain equipment and cold-chain transport service.

Holding the concept of “High quality with Low cost and Best service", CIMC Cold Cloud focuses on providing the optimal PCM, temperature recorders, cold-chain boxes and professional cold-chain transport service . We have professional and high-quality R&D andmanagement team; We have  experienced technical experts in medicine cold-chain logistics. We have four production bases of cold-chain equipment in Beijing, Hangzhou, Chengdu and Qingdao. We have more than 34 branch offices in provincial capitals and other transit hubs. Our distribution range can radiatemore than 1,000 cities.  In order to provide customers with safe and relievedcold-chain delivery services, we have established 7000 m³ refrigerating house in Beijing, Shanghai, Guangzhou, Hangzhou, Chengdu, Shijiazhuang, Wuhan and other transit hubs, which can provide sample storage service and so on.




Singlera Genomics Inc., a fast growing company focusing on non-invasive genetic testing, was co-founded in July 2014 in San Diego, California by Professor Yuan Gao (Johns Hopkins University), Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang (CEO), Mr. Qiang Liu (COO), and Dr. Rui Liu (CTO). The company currently has an R&D center in La Jolla, California, and a business and clinical operation site in Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics.

In the past decade, Professor Gao, Professor Zhang and Dr. Liu have made outstanding achievements in their respective scientific research fields, and have published hundreds of research papers in top level scientific journals. These publications include 20+ papers in Cell, Nature, and Science. In recent years Professor Gao, Professor Zhang, and Dr. Liu have expanded their efforts to translational diagnostics, and have applied their expertise to develop genetic tests. Singlera is committed to the application of Next Generation Sequencing technologies, to diagnose genetic diseases and disorders.

Singlera’s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.



Since established in March 2015, Sichuan Gezhi Big Data Technology Co. Ltd has specialized in R&D solutions for gene data processing technology. It is committed to computing devices and services in a more convenient and high-efficiency way, to benefit precision medical clients. The latest released Xiphias high-performance bioinformatics computing platform, equipped with self-developed gene data processing chip, largely optimizes and accelerates wholly computing process. It successfully integrates with well-optimized bioinformatics processing software and FPGA hardware-specific advantages.
Xiphais, hardware-based acceleration, it enables to format FASTQ-to-VCF process flow within 2.5h, involving with 30 depth Whole Genomics Sequence (WGS). With the advantages of speed-up 10 times compared to conventional computing methods, Xiphais clusters shorten it in 5 mins possible. Moreover, Xiphais is several times faster than conventional GZIP algorithm, of which lossless and lossy compression rate are 2.5 and 5 times respectively. Not just a high-efficiency compression solution from FASTQ-to-VCF process flow, more importantly, Xiphais has concentrated one-click access to raw data, annotated report and ultimate recommendation interpretation.